While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a closer look at particularly stock-shaking upgrades and downgrades -- just in case their reasoning behind the call makes sense.
What: Shares of NPS Pharmaceuticals, (NASDAQ:NPSP) slipped 1% today after Jefferies downgraded the biotechnology company from buy to hold.
So what: Along with the downgrade, analyst Eun Yang reiterated his price target of $38, representing very little upside to yesterday's close. While momentum traders might be attracted to the stock's sharp surge over the past year, Yang thinks that NPS' growth prospects, although still quite attractive, are now baked well into the valuation.
Now what: According to Jefferies, NPS' risk/reward trade-off isn't too appealing at this point. "Solid Gattex U.S. launch in 2013 and anticipation of bigger Natpara opportunity resulted in strong stock performance," noted Yang. "Now trading at ~17.2x EV/'14 revenue vs. ~16.1x for BioMarin and ~17.5x for Alexion, we view near term, potential of Gattex/Revestive and Natpara is largely priced in."
Given NPS' seemingly lofty relative and absolute valuation, it's easy to understand Jefferies' cautious stance.
More compelling ways to grow
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his six carefully chosen picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.
Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends BioMarin Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.